Key points are not available for this paper at this time.
In parallel with improvements in treatment of advanced prostate cancer, a clinically meaningful increase in mean survival was observed in men with de novo mCSPC in Sweden between 2008 and 2020 in this study.
Corsini et al. (Mon,) studied this question.